Participants
In this cross-sectional study, we included patients with MCI from two independent cohorts, based on complete availability of plasma p-tau217, CSF Aβ42/Aβ40, Aβ-PET and APOE ε4 genotyping. Our model training cohort, BioFINDER-1 (NCT01208675), recruited patients between January 2010 and January 2015 and our validation cohort, BioFINDER-2 (NCT03174938), started recruitment in May 2017. In both cohorts, the patients were consecutively recruited from secondary memory clinics in the southern part of Sweden, where most of the study participants were referred directly from primary care, as described below. In Supplementary Information, we demonstrate that the included BioFINDER-1 and BioFINDER-2 populations (that is, with full biomarker availability) were similar to the nonincluded participants due to lack of data for one or more biomarkers (Supplementary Tables 7 and 8)10,
